Oleoylethanolamide (OEA)

Tier 3 — weak evidence · Satiety · Metabolic · Endocannabinoid-like

A monounsaturated fatty acid ethanolamide produced endogenously in the small intestine during fat ingestion, acting at PPAR-alpha to signal satiety. Oral supplementation in humans modestly reduces food intake, waist circumference, and LDL. Structurally related to the endocannabinoid anandamide but does not activate cannabinoid receptors — instead it suppresses appetite via PPAR-alpha. A complementary mechanism to GLP-1 agonists and fibre. Safety profile in short-term trials is good but long-term data are limited.

Dose: 100–300 mg before meals, 1–3 times daily